(pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous ... - Business Wire (press release)

(pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous ... Business Wire (press release) “We are encouraged by the positive impact that KEYTRUDA has had on many cancer patients, including those with previously treated recurrent or metastatic head and neck cancer, and we remain confident that KEYTRUDA is an important therapy for this ... and more »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vCyGNb
via IFTTT